ClinicalTrials.gg
CompletedNCT01954121Updated Aug 15, 2017Results posted

Open-label, Randomized, Active-controlled Study of LEV Used as Monotherapy in Patients With Partial-Onset Seizures

A Phase 3 interventional study of Levetiracetam and Carbamazepine in Epilepsy and Partial Seizures, sponsored by UCB Pharma SA. Completed at 28 sites in China. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2017-08-15.

Sponsored by UCB Pharma SA (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
436
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
5th of 60
436 · median 94
Started
2013
with 2 others
Phase 3
28 of 60
2 open now
Registered
48th of 60
by date
Lead sponsor
3 of 60
UCB Pharma SA

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 5th largest by enrollment, is one of 3 that started in 2013, is one of 28 in phase 3, and was the 48th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 16 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

To demonstrate the non-inferiority of Levetiracetam (1000 mg/day) versus Carbamazepine Immediate-Release (400 mg/day) used as monotherapy for at least 6 months in a Chinese population with newly or recently diagnosed Epilepsy who are experiencing Partial-Onset Seizures (POS).

03

Conditions studied

  • Epilepsy
  • Partial Seizures

Keywords

  • Levetiracetam
  • Keppra
  • Monotherapy
  • China
  • Epilepsy
  • Partial-onset Seizures
04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is of Chinese origin and ≥ 16 years of age
  • Subject is newly or recently diagnosed with Epilepsy, having experienced unprovoked Partial-Onset Seizures (POS)
  • Subject has experienced at least 2 unprovoked seizures in the year preceding randomization, of which at least 1 unprovoked seizure occurred in the 3 months preceding randomization
  • Subject has had an Electroencephalogram (EEG) and a brain Computed Tomography (CT) scan or brain Magnetic Resonance Imaging (MRI) scan consistent with a diagnosis of Epilepsy with POS

Exclusion criteria

Exclusion Criteria:

  • Subject tests positive for human leukocyte antigen major histocompatibility complex, class I,B (HLA-B)* 1502 allele
  • Subject has a history or presence of seizures of other types than Partial-Onset Seizures (POS)
  • Subject has only experienced type IA nonmotor seizures
  • Subject has a history or presence of seizures occurring only in clustered patterns
  • Subject has a history of clinical or Electroencephalogram (EEG) findings suggestive of Idiopathic Generalized Epilepsy prior to randomization
  • Subject has current or previous diagnosis of pseudoseizures, conversion disorders, or other nonepileptic ictal events that could be confused with seizures
  • Subject has a history of Status Epilepticus
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
436 participants (actual)

Study arms

  • Experimental
    Levetiracetam

    Levetiracetam 1000 mg/day

    Drug: Levetiracetam

  • Active comparator
    Carbamazepine

    Carbamazepine 400 mg/day

    Drug: Carbamazepine

Interventions

  • Immediate release film-coated tablets at strengths of 250 mg and 500 mg. * Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid) * Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid * Down-titration Period (Week 30 up to Week 33)

    Also known as: Keppra

  • Immediate release tablets at a strength of 200 mg. * Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd) * Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid * Down-titration Period (Week 30 up to Week 33)

    Also known as: Tegretol

06

What researchers measure

Primary outcomes

  1. Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period

    Time frame: 6-months Evaluation Period (From Week 4 to Week 30)

Secondary outcomes

  1. Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period

    Time frame: From Week 1 to Week 30

  2. Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period

    Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.

    Time frame: From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)

  3. Time to First Seizure During the Evaluation Period

    Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.

    Time frame: From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)

  4. Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug

    Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.

    Time frame: From Randomization (Week 1) up to Evaluation Visit (Week 30)

07

Results

Posted Aug 11, 2016

Participant flow

This study started to enroll subjects in China in September 2013.

Participant flow — Overall Study
MilestoneLevetiracetamCarbamazepine-IR
Started220216
Completed93125
Not completed12791
Withdrew: Lack of efficacy9441
Withdrew: Protocol violation02
Withdrew: Lost to follow-up56
Withdrew: Withdrawal by subject1812
Withdrew: Pregnancy11
Withdrew: Ae, serious fatal10
Withdrew: Ae, non-serious non-fatal522
Withdrew: Sae, non-fatal14
Withdrew: Non-compliant with study procedures10
Withdrew: Non-compliant patient11
Withdrew: Subject did not follow instructions02

Outcome measures

PrimaryProportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period
Time frame:
6-months Evaluation Period (From Week 4 to Week 30)
Reported as:
Number · percentage of subjects
Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period
percentage of subjectsLevetiracetam (Per Protocol Set)Carbamazepine-IR (Per Protocol Set)
Proportion of Subjects Remaining Seizure Free During the 6-months Evaluation Period47.368.4
Statistical analysis
  • Levetiracetam (Per Protocol Set) vs Carbamazepine-IR (Per Protocol Set) · Adjusted difference in proportions: -22.9 · 95% CI -33.1 to -12.6
SecondaryProportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period
Time frame:
From Week 1 to Week 30
Reported as:
Number · percentage of subjects
Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period
percentage of subjectsLevetiracetam (Per Protocol Set)Carbamazepine-IR (Per Protocol Set)
Proportion of Subjects Retained in the Study for the Duration of the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period48.470.2
SecondaryTime to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period

Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.

Time frame:
From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)
Reported as:
Number · events
Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period
eventsLevetiracetam (Per Protocol Set)Carbamazepine-IR (Per Protocol Set)
Time to First Seizure or Discontinuation Due to an Adverse Event (AE) / Lack of Efficacy (LOE) During the Evaluation Period8845
SecondaryTime to First Seizure During the Evaluation Period

Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.

Time frame:
From first day in the Evaluation Period (Week 4) up to end of the Evaluation Period (Week 30)
Reported as:
Number · events
Time to First Seizure During the Evaluation Period
eventsLevetiracetam (Per Protocol Set)Carbamazepine-IR (Per Protocol Set)
Time to First Seizure During the Evaluation Period8739
SecondaryTime to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug

Number of qualifying events is reported because it is the only descriptive measure available from the proportional hazards model, that was applied.

Time frame:
From Randomization (Week 1) up to Evaluation Visit (Week 30)
Reported as:
Number · events
Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug
eventsLevetiracetam (Per Protocol Set)Carbamazepine-IR (Per Protocol Set)
Time to First Seizure During the Period Covering the Up Titration Period, Stabilization Period, and Evaluation Period From the First Dose of Study Drug9757

Adverse events

Collected over Adverse Events (AEs) were collected from Visit 1 (Week 0) until Safety Follow Up Visit (Week 35).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Levetiracetam (Safety Set)—9/218 (4.1%)92/218 (42.2%)
Carbamazepine-IR (Safety Set)—11/215 (5.1%)93/215 (43.3%)
Most frequent serious events
Showing 10 of 21
Most frequent serious events
EventLevetiracetam (Safety Set)Carbamazepine-IR (Safety Set)
Abortion inducedSurgical and medical procedures1/2182/215
Status epilepticusNervous system disorders2/2181/215
Thrombocytopenic purpuraBlood and lymphatic system disorders0/2181/215
Peripheral swellingGeneral disorders0/2181/215
Lung infectionInfections and infestations0/2181/215
Hand fractureInjury, poisoning and procedural complications1/2181/215
OverdoseInjury, poisoning and procedural complications0/2181/215
Patella fractureInjury, poisoning and procedural complications0/2181/215
Rib FractureInjury, poisoning and procedural complications0/2181/215
Breast cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/2181/215
Most frequent other events
Most frequent other events
EventLevetiracetam (Safety Set)Carbamazepine-IR (Safety Set)
NasopharyngitisInfections and infestations40/21832/215
DizzinessNervous system disorders33/21818/215
SomnolenceNervous system disorders20/2187/215
HeadacheNervous system disorders19/21816/215
Upper respiratory tract infectionInfections and infestations12/21816/215
Blood cholesterol increasedInvestigations6/21811/215
Gamma-glutamyltransferase increasedInvestigations2/21811/215
White blood cell count decreasedInvestigations1/21811/215
Urinary tract infectionInfections and infestations11/2185/215

Baseline characteristics

The Baseline Characteristics refers to the Safety Set (SS) which consists of all subjects who were randomized and received at least 1 dose of trial medication.

Age, Categorical
Age, Categorical(Participants)Levetiracetam (Safety Set)Carbamazepine-IR (Safety Set)Total Title
<=18 years202242
Between 18 and 65 years184186370
>=65 years14721
Age, Continuous
Age, Continuous(years)Levetiracetam (Safety Set)Carbamazepine-IR (Safety Set)Total Title
mean (standard deviation)37.8 ± 16.233.3 ± 14.335.6 ± 15.4
Sex: Female, Male
Sex: Female, Male(Participants)Levetiracetam (Safety Set)Carbamazepine-IR (Safety Set)Total Title
Female10694200
Male112121233
08

Study locations

28 sites
  • 13
    Beijing, China
  • 16
    Changchun City, China
  • 10
    Chengdu, China
  • 5
    Chengdu, China
  • 4
    Chongqing, China
  • 26
    Guangzhou City, China
  • 11
    Guangzhou, China
  • 1
    Guangzhou, China
  • 20
    Guangzhou, China
  • 24
    Hangzhou, China
  • 22
    Harbin, China
  • 29
    Kunming, China
  • 23
    Nanjing City, China
  • 6
    Nanjing City, China
  • 8
    Nanjing City, China
  • 21
    Nanjing, China
  • 27
    Qingdao, China
  • 14
    Shanghai, China
  • 15
    Shanghai, China
  • 18
    Shanghai, China
  • 2
    Shanghai, China
  • 19
    Shijiazhuang, China
  • 3
    Suzhou, China
  • 9
    Taiyuan, China
  • 25
    Tianjin, China
  • 12
    Wuhan, China
  • 7
    Xi'an, China
  • 17
    Xian, China
09

References and documents

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Sep 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2013
First posted
Oct 1, 2013
Start
Sep 2013
Primary completionActual
Sep 2015
CompletionActual
Sep 2015
Results first posted
Aug 11, 2016
Last update
Aug 15, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 15, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01954121
Lead sponsor
UCB Pharma SA
Responsible party
Sponsor
First posted
Oct 1, 2013
Start date
Sep 2013
Primary completion
Sep 2015
Completion
Sep 2015
Results posted
Aug 11, 2016
Last update
Aug 15, 2017

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion